<DOC>
	<DOCNO>NCT01350310</DOCNO>
	<brief_summary>BACKGROUND . In patient non-ischemic dilated cardiomyopathy , intracoronary stem cell transplantation show improve exercise capacity , reduce ventricular remodelling improve 1-year survival . Pre-clinical data demonstrate stem cell effect diseased heart enhance direct intramyocardial delivery route . AIMS . 1 . To evaluate safety efficacy intramyocardial stem cell therapy patient non-ischemic dilated cardiomyopathy . 2 . To directly compare clinical effect intracoronary intramyocardial stem cell delivery . METHODS . Of 60 patient dilate cardiomyopathy , 30 randomize intramyocardial transplantation CD34+ cell ( Study Group ) , 30 receive intracoronary stem cell therapy ( Control Group ) . In group peripheral blood stem cell mobilise daily subcutaneous injection filgrastim ; CD34+ cell collect via apheresis label technetium . In Study Group electromechanical mapping use identify viable myocardium intramyocardial injection target area perform NOGA catheter . In Control group patient undergo myocardial perfusion scintigraphy CD34+ cell inject intracoronary artery supply segment reduce viability . Patients follow 1 year . Primary endpoint include change leave ventricular ejection fraction leave ventricular dimension ( measure echocardiography ) . Secondary endpoint include change exercise capacity change NT-proBNP value . HYPOTHESES . 1 . At 1 year , intramyocardial stem cell therapy associate improved leave ventricular ejection fraction , reduce leave ventricular dimension , improve exercise capacity reduce level NT-proBNP . 2 . Beneficial effect intramyocardial stem cell therapy superior observe intracoronary stem cell delivery .</brief_summary>
	<brief_title>Safety Efficacy Study Intramyocardial Stem Cell Therapy Patients With Dilated Cardiomyopathy</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Cardiomyopathy , Dilated</mesh_term>
	<criteria>Established dg . dilate CMP ( define accord ESC position statement absence stenotic lesion coronary angiography , congenital heart disease , primary valve disease echocardiography , history hypertension alcohol abuse1 ) leave ventricular ejection fraction &lt; 30 % NYHA functional class III IV least 3 month referral Optimal medical management least 6 month Left ventricular aneurysm thrombus Hematologic disease Multiorgan failure Active malignancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Heart failure</keyword>
	<keyword>Dilated cardiomyopathy</keyword>
	<keyword>Stem cell</keyword>
</DOC>